Floatz logo

PX-866

Glioblastoma

NCIC Clinical Trials GroupPhase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
65/ 100

Competitive context

354 Active assets in the Glioblastoma cohort.

Asset / SponsorPhaseRating
Irinotecan
Beijing Sanbo Brain Hospital
Phase 2/3BBB
Depatuxizumab Mafodotin
AbbVie
Phase 3BB
CARMUSTINE
Leland Metheny
Phase 3BB
Irinotecan
University of Cincinnati
Phase 3BB
(+)-VINCRISTINE
University of Cincinnati
Phase 3BB

View all 50 →

Same molecule, other indications

PX-866 is also rated in:

non-small cell lung carcinomaDormant
CCC
Indicative ·
50 / 100
View asset →
Advanced BRAF-mutant CancersDormant
CCC
Indicative ·
48 / 100
View asset →
prostate cancerDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →